Image credit: shutterstock
South Korea-based startup Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, has announced that it is collaborating with Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC) in the US, on early drug discovery research.
Under the terms of the agreement, Standigm will use Nashville Bioscience's extensive, de-identified genomic and clinical data to build new, customized AI models for drug discovery. The mission of the collaboration is to accelerate early-stage drug discovery.
Carl Foster, chief business officer at Standigm said, "Data is undoubtedly a pivotal part of AI drug discovery. Leveraging Nashville Bioscience's data will add great value to our platforms, enabling us to make the most of customizable and explainable features. We will also be able to better understand the relationship between genetic variants and corresponding phenotypes."
Standigm's customers will leverage data of interest via the Standigm AI platforms that were designed to surface insights hidden in large-scale data. With this streamlined approach, customers don't have to worry about sourcing or integrating proprietary data on their own.
